NTRA News and Press, Natera Inc. From 05/10/24

2024-05-10 08:00:05 ET Catherine Ramsey Schulte from Robert W. Baird issued a price target of $117.00 for NTRA on 2024-05-10 06:50:00. The adjusted price target was set to $117.00. At the time of the announcement, NTRA was trading at $95.55. The overall price target cons...

2024-05-09 23:28:04 ET Natera, Inc. (NTRA) Q1 2024 Earnings Conference Call May 09, 2024 04:30 PM ET Company Participants Mike Brophy - Chief Financial Officer Steve Chapman - Chief Executive Officer Solomon Moshkevich - President, Clinical Diagnostics Alex A...

2024-05-09 17:47:18 ET Gainers: Inseego ( INSG ) +22% . Natera ( NTRA ) +18% . CareDx ( CDNA ) +13% . SoundHound  ( SOUN ) +13% . Funko ( FNKO ) +12% . Losers: MacroGenics ( MGNX ) -62% . Progyny ( PGNY...

2024-05-09 16:27:33 ET More on Natera Natera: Capitalizing On The Positive Momentum Of Personalized Medicine Natera, Inc. (NTRA) Q4 2023 Earnings Call Transcript Natera upgraded at Bernstein on gross margin trajectory Carpenter Technology, Natera, ethereum pi...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for the first quarter ended March 31, 2024. Recent Strategic and Financial Highlights Achieved positive cash flow of approximately $3.0 million 1 in the first ...

Expanded EBLIS study with up to 12 years of clinical follow-up across all subtypes of breast cancer Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced a new publication in JCO Precision Oncology reporting on the ability of its pers...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that it will release results for its first quarter ended March 31, 2024, after the market close on May 9, 2024. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4...

Backed by large clinical validation study with over 650 RhD-negative patients with confirmed outcomes, resulting in 100% sensitivity and >99% specificity Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced the launch of a new...

2024-04-24 09:30:00 ET Summary Artisan Partners is an independent investment management firm focused on providing high value-added, active investment strategies to sophisticated clients globally. The portfolio solidly outperformed the MSCI AC World Index. Holdings in health ca...

2024-04-23 09:30:00 ET Summary Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. In the quarter ended March 31, 2024, Baron Health Care Fund advanced 8.92% compared wi...